Skip to Content

'
George J. Chang, MD, MS, FACS, FASCRS

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Medical Director, Colorectal Center, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief, Section of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Clinical Operations, Minimally Invasive and New Technologies in Oncologic Surgery Program, The University of Texas MD Anderson Cancer Center, Houston

Research Interests

Cancer treatment outcomes research.  Clinical epidemiology of cancer treatment outcomes.  Decision modeling for cancer treatment.

Clinical trials in cancer therapy.

Education & Training

Degree-Granting Education

2007 The University of Texas Health Science Center at Houston Medical School, Houston, TX, MS, Masters of Science in Clinical Research
1995 University of California, Los Angeles, CA, MD, Doctor of Medicine
1991 University of California, Berkeley, CA, BA, Magna cum Laude, Biochemistry

Postgraduate Training

7/2003-6/2004 Clinical Fellow, Colon and Rectal Surgery, Mayo Clinic, Rochester, MN
7/2002-6/2003 Chief Resident, Surgery, University of California, San Francisco, CA
7/1998-6/2001 Post-doctoral Research Fellow, Surgery, University of California, San Francisco, CA
7/1996-6/2002 Resident, Surgery, University of California, San Francisco, CA
7/1995-6/1996 Intern, Surgery, University of California, San Francisco, CA

Board Certifications

2005 American Board of Colon and Rectal Surgery
2004 American Board of Surgery

Selected Publications

Peer-Reviewed Original Research Articles

1. Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, Vauthey JN, Rogers JE, Ohinata A, Pathak P, Sethi S, Phillips JK, Crane CH, Wolff RA. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 5(22):11133-42, 11/30/2014. e-Pub 10/17/2014. PMID: 25373735.
2. Monson JR, Probst CP, Wexner SD, Remzi FH, Fleshman JW, Garcia-Aguilar J, Chang GJ, Dietz DW, Consortium for Optimizing the Treatment of Rectal Cancer (OSTRiCh). Failure of evidence-based cancer care in the United States: the association between rectal cancer treatment, cancer center volume, and geography. Ann Surg 260(4):625-31; discussion 631-2, 10/2014. PMID: 25203879.
3. Massarweh NN, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Cormier JN, Feig BW, Chang GJ. Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol 32(27):2967-74, 9/2014. PMID: 25513452.
4. Chang GJ, Greenberg CC, Kozower BD, Boughey JC, Francescatti A, Mckellar DP, Winchester DP. NCDB and ACS-CRP: Working together to develop risk-stratified strategies for surveillance. Bull Am Coll Surg 99(8):57-8, 8/2014. PMID: 25145051.
5. Chang GJ. 'Watch-and-wait' for rectal cancer: what's the way forward? Oncology (Williston Park) 28(7):617-8, 7/2014. PMID: 25144283.
6. Hyngstrom JR, Tzeng CW, Beddar S, Das P, Krishnan S, Delclos ME, Crane CH, Chang GJ, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: Ten-year institutional experience. J Surg Oncol 109(7):652-8, 6/2014. e-Pub 2/10/2014. PMID: 24510523.
7. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 120(8):1162-70, 4/15/2014. e-Pub 1/28/2014. PMCID: PMC3981916.
8. Phatak UR, Li LT, Karanjawala B, Chang GJ, Kao LS. Systematic review of educational interventions for ostomates. Dis Colon Rectum 57(4):529-37, 4/2014. PMID: 24608311.
9. Massarweh NN, Chiang YJ, Xing Y, Chang GJ, Haynes AB, You YN, Feig BW, Cormier JN. Association Between Travel Distance and Metastatic Disease at Diagnosis Among Patients With Colon Cancer. J Clin Oncol 32(9):942-8, 3/20/2014. e-Pub 2/10/2014. PMID: 24516014.
10. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys 88(2):301-5, 2/1/2014. e-Pub 12/5/2013. PMID: 24315563.
11. Phatak UR, Kao LS, You YN, Rodriguez-Bigas MA, Skibber JM, Feig BW, Nguyen S, Cantor SB, Chang GJ. Impact of Ileostomy-Related Complications on the Multidisciplinary Treatment of Rectal Cancer. Ann Surg Oncol 21(2):507-12, 2/2014. e-Pub 10/2/2013. PMCID: PMC4026258.
12. Abbas MA, Chang GJ, Read TE, Rothenberger DA, Garcia-Aguilar J, Peters W, Monson JR, Sharma A, Dietz DW, Madoff RD, Fleshman JW, Greene FL, Wexner SD, Remzi FH, Consortium for Optimizing Surgical Treatment of Rectal Cancer. Optimizing rectal cancer management: analysis of current evidence. Dis Colon Rectum 57(2):252-9, 2/2014. PMID: 24401889.
13. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 12/15/2013. e-Pub 10/1/2013. PMID: 24089344.
14. Lee S, Reha JL, Tzeng CW, Massarweh NN, Chang GJ, Hetz SP, Fleming JB, Lee JE, Katz MH. Race Does Not Impact Pancreatic Cancer Treatment and Survival in an Equal Access Federal Health Care System. Ann Surg Oncol 20(13):4073-9, 12/2013. e-Pub 9/4/2013. PMID: 24002535.
15. Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB. The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. Ann Surg Oncol 20 Suppl 3:S500-8, 12/2013. e-Pub 2/10/2013. PMID: 23397153.
16. Eng C, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CH. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer 119(21):3769-75, 11/1/2013. e-Pub 8/20/2013. PMID: 24037775.
17. Badgwell B, Stanley J, Chang GJ, Katz MH, Lin HY, Ning J, Klimberg SV, Cormier JN. Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery. J Surg Oncol 108(3):182-6, 9/2013. e-Pub 6/26/2013. PMID: 23804149.
18. Bednarski BK, Chang GJ. Ultra-low anterior resection following neoadjuvant chemoradiation for rectal cancer: The end of the 1-cm rule? Seminars in Colon and Rectal Surgery 24(3):159-163, 9/2013.
19. Russell MC, You YN, Hu CY, Cormier JN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Nelson H, Chang GJ. A Novel Risk-Adjusted Nomogram for Rectal Cancer Surgery Outcomes. JAMA Surg 148(8):1-9, 8/2013. e-Pub 6/26/2013. PMCID: PMC3947615.
20. Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg 100(8):E1-E33, 7/2013. PMID: 23754654.
21. Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix: The Prognostic Impact of Histological Grade. Ann Surg 257(6):1072-8, 6/2013. e-Pub 9/2012. PMCID: PMC3855996.
22. Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer 119(10):1900-7, 5/15/2013. e-Pub 2/13/2013. PMCID: PMC3673539.
23. Bowles TL, Hu CY, You NY, Skibber JM, Rodriguez-Bigas MA, Chang GJ. An individualized conditional survival calculator for patients with rectal cancer. Dis Colon Rectum 56(5):551-9, 5/2013. PMCID: PMC3673550.
24. Yi M, Xu J, Liu P, Chang GJ, Du XL, Hu CY, Song Y, He J, Ren Y, Wei Y, Yang J, Hunt KK, Li X. Comparative analysis of lifestyle factors, screening test use, and clinicopathologic features in association with survival among Asian Americans with colorectal cancer. Br J Cancer 108(7):1508-14, 4/16/2013. e-Pub 3/7/2013. PMCID: PMC3629437.
25. Chagpar R, Chiang YJ, Xing Y, Cormier JN, Feig BW, Rashid A, Chang GJ, You YN. Neuroendocrine Tumors of the Colon and Rectum: Prognostic Relevance and Comparative Performance of Current Staging Systems. Ann Surg Oncol 20(4):1170-8, 4/2013. e-Pub 12/1/2012. PMID: 23212760.

Editorials

1. Krishnan S, Chang GJ. Kras mutations and rectal cancer response to chemoradiation- are we closer to personalization of therapy? Ann Surg Oncol 20(11):3359-62, 10/2013. e-Pub 7/18/2013. PMID: 23864308.
2. Chang GJ. Emphasizing Surgery for Colon Cancer. Dis Colon Rectum 56(7):805-7, 7/2013. PMID: 23739185.
3. Chang GJ. Challenge of Primary Tumor Management in Patients With Stage IV Colorectal Cancer. J Clin Oncol 30(26):3165-6, 9/2012. e-Pub 8/2012. PMID: 22869881.

Last updated: 12/23/2014